Zoya Gluzman
Keine laufenden Positionen mehr
Profil
Zoya Gluzman worked as a Principal at VESSL Therapeutics Ltd.
and as a Chief Technology Officer at GeneGrafts Ltd.
She holds an MBA and a doctorate degree from Technion-Israel Institute of Technology.
Ehemalige bekannte Positionen von Zoya Gluzman
| Unternehmen | Position | Ende |
|---|---|---|
VESSL Therapeutics Ltd.
 VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Corporate Officer/Principal | - |
GeneGrafts Ltd.
 GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Zoya Gluzman
| Technion-Israel Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
GeneGrafts Ltd.
GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Health Technology |
VESSL Therapeutics Ltd.
VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Health Technology |
